Interference from anti-drug antibodies on the quantification of insulin: a comparison of an LC-MS/MS assay and immunoassays

2024-9-12

Highlights of the 15th Japan Bioanalysis Forum Symposium

2024-9-12

Patient-centric microsampling for abrocitinib pharmacokinetics: multiple-analytes assay bridging using Tasso device

2024-9-5

Quantification of osilodrostat in horse urine using LC/ESI–HRMS to establish an elimination profile for doping control

2024-9-5

UPLC–MS/MS method for fluconazole determination in plasma and its application in Mexican patients with candidaemia

2024-9-5

A comprehensive LC–MS based study of factors influencing biotinylation of critical reagents

2024-9-4

Assessing prognosis by quantifying FcγRIIa on fixed platelets

2024-9-4

LC-MS/MS-based bioanalysis of branched-chain and aromatic amino acids in human serum

2024-8-19

The investigation of connection between anticoagulant therapy and vitamin K homologues in human determined by LC–MS/MS

2024-8-14

Correction

2024-8-9

Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum

2024-8-9

Quantitation of anacetrapib in human and animal adipose by liquid chromatography with mass spectrometric detection

2024-8-9

DoE-assisted HPLC method development and validation of enzalutamide and repaglinide in rat plasma

2024-8-8

Comparative pharmacokinetic study of Anisodamine Hydrobromide tablets and injection in septic acute lung injury rats

2024-8-8

Hollow Fiber-in-Syringe Equilibrium Sampling Through Supported-Liquid Membrane for Evaluation of Drug-Plasma Binding

2024-8-8

The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays

2024-8-5

A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays

2024-8-5

Can capillary microsampling facilitate a clinical pharmacokinetics study of cefazolin in critically ill children?

2024-7-29

Bioanalysis of free antisense oligonucleotide payload from antibody–oligonucleotide conjugate by hybridization LC-MS/MS

2024-7-23

Free serum concentrations of antibiotics determined by ultrafiltration: extensive evaluation of experimental variables

2024-7-23

Critical reagent considerations for immunogenicity assay development for bispecific biotherapeutic candidates

2024-7-18

Flow cytometry vs conventional methods for the evaluation of anti-PF4/heparin antibodies: a single center study

2024-7-18

Development and application of a multi-sugar assay to assess intestinal permeability

2024-7-18

Estimation of CDK inhibitors by RP-HPLC: application for pharmacokinetic interactions studies with PPIs

2024-7-17

Evaluating the “Blueness” of a method: the new drift to assess practicality in (green) bioanalysis

2024-7-17

Simultaneous estimation of rutin and donepezil through RP-HPLC: implication in pharmaceutical and biological samples

2024-7-16

Mitigating target interference challenges in bridging immunogenicity assay to detect anti-tocilizumab antibodies

2024-7-16

The fusion of microfluidics and artificial intelligence: a novel alliance for medical advancements

2024-7-9

Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum

2024-7-3

Bioanalysis Rising Star Award 2024: interviews with the finalists

2024-7-1

Role of miRNA-21 in cancer and its application in electrochemical bioanalysis

2024-7-1

Biodistribution of lipid nanoparticle, eGFP mRNA and translated protein following subcutaneous administration in mouse

2024-6-28

A hybrid IA-LC-MS/MS method for adrenocorticotropic hormone(1–24) to support interpretation of low-dose cosyntropin-stimulation test

2024-6-28

Qualification of a 21-valent pneumococcal urine antigen detection assay and development of clinical positivity cutoffs

2024-6-28

Unique challenges required reassessment and alterations to critical reagents to rescue a neutralizing antibody assay

2024-6-17

16 ^th GCC Closed Forum: ICH M10 implementation; NGS, qPCR/dPCR, flow cytometry validation; tissue biomarkers; IS response; immunogenicity harmonization; bioanalytical industry status

2024-6-12

Evaluation of the bioavailability of a Tamiflu taste-masking pediatric formulation using a juvenile pig model and LC-MS/MS

2024-6-11

Optimized LC-MS/MS methods for quantifying antibody–drug conjugate payloads in cell culture media containing phenol red

2024-6-11

Development and validation of carbodiimide-activated ELISA plate for quantifying IgG levels against <i>Streptococcus pneumoniae</i> capsular polysaccharides

2024-6-10

Development of a sensitive LC-MS/MS assay to support human microdose study for an oral agonist of the GLP-1 receptor ¹

2024-6-10

Comparison of multiple bioanalytical assay platforms for the quantitation of siRNA therapeutics

2024-6-6

Inclusion of dilution quality control samples in quantitative LC-MS bioanalysis

2024-6-6

An LC-MS/MS method for the determination of Lifitegrast in human plasma and tear and its application in the pharmacokinetic study

2024-6-2

Tuberculosis diagnosis versus GeneXpert ^® MTB/RIF formats

2024-5-22

GC-NPD analysis of topiramate in capillary dried plasma: assessing chemical dependency pharmacotherapy

2024-5-20

Internal standard variability: root cause investigation, parallelism for evaluating trackability and practical considerations

2024-5-9

Feedback from the Science Café roundtables at the ninth European Bioanalysis Forum Young Scientist Symposium: optimizing the work–life balance in a bioanalytical laboratory

2024-5-9

The case for bioanalytical analyzer

2024-5-9

2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody <u>(PART 1A</u> – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis <u>PART 1B</u> - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/…

2024-5-2

Use of RNA biomarkers in the antidoping field

2024-4-23